The tumor microenvironment (TME) is greatly multifaceted and immune escape is an imperative attribute of tumors fostering tumor progression and metastasis. Based on reports, the restricted achievement attained by T cell immunotherapy reflects the prominence of emerging other innovative immunotherapeutics, in particular, natural killer (NK) cells-based treatments. Human NK cells act as the foremost innate immune effector cells against tumors and are vastly heterogeneous in the TME. Currently, there exists a rapidly evolving interest in the progress of chimeric antigen receptor (CAR)-engineered NK cells for tumor immunotherapy. CAR-NK cells superiorities over CAR-T cells in terms of better safety (e.g., absence or minimal cytokine release syndrome (CRS) and graft-versus-host disease (GVHD), engaging various mechanisms for stimulating cytotoxic function, and high feasibility for ‘off-the-shelf’ manufacturing. These effector cells could be modified to target various antigens, improve proliferation and persistence in vivo, upturn infiltration into tumors, and defeat resistant TME, which in turn, result in a desired anti-tumor response. More importantly, CAR-NK cells represent antigen receptors against tumor-associated antigens (TAAs), thereby redirecting the effector NK cells and supporting tumor-related immunosurveillance. In the current review, we focus on recent progress in the therapeutic competence of CAR-NK cells in solid tumors and offer a concise summary of the present hurdles affecting therapeutic outcomes of CAR-NK cell-based tumor immunotherapies.
Background: VEGF gene polymorphisms can induce either increase or inhibition of VEGF secretion, with altered promoter activity.
Aim:We investigated the association of the VEGFR-2 and -2578C\A polymorphism in the VEGF gene with Lung cancer risk in Babylon province. Methodology: VEGFR-2 level was measured by Enzyme Linked Immunoabsorbant Assay ELISA and Genotyping of the VEGF-gene variation (-2578A\C) was performed using the amplification refractory mutation system PCR. We investigated the association of VEGF gene variants with different clinicopathological features of lung cancer patients.Results: No significant difference was seen of the VEGFR-2 levels in lung cancer patients when compared with control group (P=092), the allelic frequency of -2578 A\C VEGF gene no difference was seen in patients lung cancer (p=0.652). Hardy-Weinberg equilibrium showed a significant difference cases group (p=0.016), also revealed A allele exhibits a pathological behavior and it appears in over-dominant model (p=0.05), this proves that there is significant association of -2578A\C VEGF gene in lung cancer patients.
Conclusion:Our results showed no significant association of the VEGFR-2 in lung cancer patients while showed a significant association of the VEGF -2578C\A polymorphism with LC susceptibility in Babylon province .The VEGF -2578C\A heterozygote significantly increases the risk and can be useful as a predisposing genetic marker.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.